JNJ Stock (NYSE:JNJ)
On Monday, the Janssen division of Johnson & Johnson (NYSE:JNJ) made the announcement that more than half of the patients who responded favorably to the therapy for ulcerative colitis known as Stelara (ustekinumab) in a Phase 3 trial remained in clinical remission even after receiving treatment for four years. As a result, JNJ stock declined in the market.
According to the results of the late-stage UNIFI long-term extension trial by JNJ stock, which included adults with UC, at least 65% of patients who responded to Stelara were in symptomatic remission after 44 weeks of treatment with maintenance medication.
At week 200 (four years), the proportion had increased to around 55%, and almost 96% of patients were no longer receiving corticosteroid medication, which is associated with considerable adverse effects.
71% of patients who were given Stelara as their first biologic treatment were in symptomatic remission after 44 weeks, and 67% of those patients were in remission after 200 weeks.
Throughout the study, it was discovered that the safety profile of Stelara was determined to be equivalent to that of patients who were given a placebo.
The information was presented as part of a European medical conference focusing on the gastrointestinal.
The presenting author of the study, Waqqas Afif, observed that the final LTE results of the UNIFI study demonstrated that STELARA can be an effective long-term treatment option for patients with moderate to severe conditions of active ulcerative colitis. This holds true even in patients who have never been treated with a biologic before. So, JNJ stock declined in the market on Monday morning.
At the McGill University Health Center in Montreal, Canada, Afif holds the position of Associate Professor in the Department of Medicine.
In 2021, sales of Stelara in the United States for illnesses such as UC and plaque psoriasis contributed an additional $9.1 billion to Johnson & Johnson’s (NYSE:JNJ) revenue.
Featured Image- Megapixl @ Mesteban100
Author Shariq Khan 
